Zentiva Italia SRL

Zentiva Italia S.r.l., established in 1995, is a pharmaceutical importer and distributor headquartered in Milan, Italy. As a subsidiary of the pan-European pharmaceutical company Zentiva, based in Prague, Czech Republic, it plays a pivotal role in delivering high-quality, affordable medicines to the Italian market. Zentiva Italia's portfolio encompasses generic drugs, specialty pharmaceuticals, and over-the-counter (OTC) products, focusing on therapeutic areas such as cardiology, oncology, respiratory conditions, and central nervous system disorders. (zentiva.it)

The company operates under the legal framework of a Società a Responsabilità Limitata (S.r.l.), a limited liability company, with a registered capital of €1,000,000 as of 2026. In 2024, Zentiva Italia reported a turnover of €98,494,313, reflecting its significant presence in the pharmaceutical distribution sector. (ufficiocamerale.it) With a dedicated team of approximately 109 employees, the company is committed to ensuring the availability of essential medicines across Italy. (ufficiocamerale.it)

Zentiva Italia S.r.l. maintains a robust distribution network to ensure the efficient delivery of pharmaceutical products throughout Italy. While specific warehouse locations are not publicly disclosed, the company's strategic positioning in Milan, a central hub for logistics, facilitates effective nationwide distribution. The company leverages advanced logistics capabilities to manage a diverse portfolio of products, ensuring timely and reliable supply to various healthcare providers, including hospitals, pharmacies, and clinics. This infrastructure supports Zentiva Italia's mission to provide accessible healthcare solutions across the country.

In Italy's pharmaceutical supply chain, Zentiva Italia S.r.l. functions primarily as a pharmaceutical importer and distributor. The company sources a wide range of pharmaceutical products from international manufacturers, including active pharmaceutical ingredients (APIs) and finished dosage forms, to meet the diverse needs of the Italian market. By importing and distributing these products, Zentiva Italia ensures the availability of essential medicines, contributing to the overall health and well-being of the Italian population.

Zentiva Italia S.r.l. demonstrates a high degree of sourcing concentration, with a total import value from India amounting to $7.0 million USD across 234 shipments. The company's portfolio is exclusively focused on cardiovascular products, specifically Ramipril and Clopidogrel, imported from a single supplier, Zentiva Private Limited. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. However, it also presents potential risks, such as supply disruptions or changes in supplier terms, which could impact Zentiva Italia's ability to meet market demand.

The shipment data reveals a stable and consistent relationship with Zentiva Private Limited, suggesting a reliable supply chain. Nonetheless, the lack of diversification in sourcing could expose Zentiva Italia to vulnerabilities, especially in the event of geopolitical issues, regulatory changes, or operational challenges faced by the supplier. To mitigate these risks, it would be prudent for Zentiva Italia to consider diversifying its supplier base and exploring alternative sources for its key products.

Zentiva Italia S.r.l.'s supply chain resilience is closely tied to its exclusive reliance on Zentiva Private Limited for the import of Ramipril and Clopidogrel. This singular sourcing strategy may limit the company's ability to adapt to supply chain disruptions or fluctuations in demand. The absence of backup suppliers for these critical products suggests a potential vulnerability in maintaining uninterrupted supply to the Italian market.

The focus on a limited number of formulations—120 unique formulations—further concentrates the supply chain, potentially impacting the company's agility in responding to market changes or regulatory shifts. Additionally, the reliance on a single supplier may expose Zentiva Italia to risks associated with that supplier's operational stability, regulatory compliance, and financial health. To enhance supply chain resilience, Zentiva Italia should consider establishing relationships with multiple suppliers and diversifying its product offerings to better withstand potential disruptions.

Zentiva Italia S.r.l.'s concentrated sourcing strategy positions the company to benefit from streamlined operations and potentially favorable terms with its sole supplier, Zentiva Private Limited. This approach may lead to cost efficiencies and a strong partnership with the supplier. However, the lack of diversification introduces risks related to supply chain disruptions, regulatory changes, and market fluctuations.

For Indian exporters seeking to become alternative suppliers to Zentiva Italia, this concentrated sourcing pattern presents an opportunity to offer competitive advantages, such as reliability, quality assurance, and compliance with European Union Good Manufacturing Practices (EU GMP). By meeting these standards and demonstrating the ability to provide consistent supply, Indian exporters can position themselves as viable partners for Zentiva Italia, potentially expanding their market presence in Europe.

In Italy, the primary regulatory authority overseeing the pharmaceutical sector is the Italian Medicines Agency (AIFA). AIFA is responsible for the evaluation, authorization, and monitoring of medicinal products to ensure their safety, efficacy, and quality. The agency operates under the framework of both national and European Union regulations, aligning with directives and regulations set forth by the European Medicines Agency (EMA). This dual framework ensures that Italy's pharmaceutical market adheres to stringent standards, facilitating the availability of safe and effective medicines to the public. (aifa.gov.it)

The marketing authorization pathway for medicinal products in Italy involves a comprehensive evaluation process. Applicants must submit a dossier containing detailed information on the product's chemical-pharmaceutical, preclinical, and clinical aspects, structured according to the Common Technical Document (CTD) format. This dossier undergoes a scientific assessment by AIFA to verify compliance with quality, safety, and efficacy requirements. Once granted, the marketing authorization is valid for five years and is renewable, ensuring continuous oversight of medicinal products in the Italian market. (aifa.gov.it)

Import licensing requirements in Italy are governed by AIFA and the Ministry of Health. Pharmaceutical companies seeking to import medicinal products must obtain the necessary authorizations, which include demonstrating compliance with Good Manufacturing Practices (GMP). GMP certification ensures that manufacturing processes meet the required standards for product quality and safety. Recognized certifications include EU GMP, WHO GMP, and PIC/S standards. Additionally, companies must hold wholesale distribution authorizations to legally distribute medicinal products within Italy. (aifa.gov.it)

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy before being released to the market. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements stipulate that product information, including the Summary of Product Characteristics (SmPC), package leaflet, and labels, be provided in Italian to ensure clear communication with healthcare professionals and patients. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the supply chain. (aifa.gov.it)

Between 2024 and 2026, several policy changes have impacted the importation of pharmaceutical products into Italy. Notably, updates to the "silenzio/assenso" procedure, in alignment with the new EC Classification Guideline on variations, have been implemented to streamline the approval process for medicinal product variations. Additionally, the Ministry of Health has reallocated competencies concerning the certification of Plasma Master Files and the import/export of human blood and its products. These changes aim to enhance regulatory efficiency and ensure the continued availability of essential medicines in the Italian market. (aifa.gov.it)

Zentiva Italia S.r.l.'s focus on cardiovascular products, specifically Ramipril and Clopidogrel, aligns with the significant demand for treatments addressing cardiovascular diseases in Italy. The decision to import these products from India reflects a strategic approach to sourcing high-quality generics that offer cost-effective solutions to the Italian healthcare system. By concentrating on these therapeutic areas, Zentiva Italia aims to meet the needs of a substantial patient population, contributing to improved health outcomes and enhanced quality of life.

Zentiva Italia's sourcing strategy emphasizes the procurement of generic drugs, particularly focusing on formulations that address prevalent health conditions such as cardiovascular diseases. The company's reliance on a single supplier, Zentiva Private Limited, for these products indicates a preference for streamlined operations and established partnerships. This approach suggests a commitment to maintaining consistent product quality and supply reliability. However, the concentration on a limited number of formulations may restrict the company's ability to diversify its product offerings and adapt to evolving market demands.

Based on its product mix, Zentiva Italia S.r.l. primarily serves the wholesale distribution segment of the Italian pharmaceutical market. By importing and distributing generic cardiovascular medications, the company caters to a broad spectrum of healthcare providers, including hospitals, clinics, and pharmacies.